Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2Unknown 1Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Gynecologic 2Gastrointestinal 2Breast 2Thoracic 1Genitourinary 1

Conditions

Colorectal Neoplasms 218Rectal Neoplasms 133Stomach Neoplasms 111Colonic Neoplasms 101Pancreatic Neoplasms 81Neoplasm Metastasis 57Esophageal Neoplasms 48Neoplasms 31Adenocarcinoma Of Esophagus 23Adenocarcinoma 21Carcinoma, Hepatocellular 20Carcinoma, Non-Small-Cell Lung 16Biliary Tract Neoplasms 16Gallbladder Neoplasms 15Cholangiocarcinoma 15Gastrointestinal Neoplasms 14Liver Neoplasms 13Lymphoma, Large B-Cell, Diffuse 12Breast Neoplasms 12Unspecified Adult Solid Tumor, Protocol Specific 11Esophageal Squamous Cell Carcinoma 11Bile Duct Neoplasms 10Recurrence 9Peritoneal Neoplasms 9Parkinson Disease 4, Autosomal Dominant Lewy Body 8Ovarian Neoplasms 8Squamous Cell Carcinoma of Head and Neck 5Head and Neck Neoplasms 5Appendiceal Neoplasms 5Advanced Gastric Cancer 5

Interventions

Carboplatin 41Paclitaxel 40pembrolizumab 38Cyclophosphamide 23Gemcitabine 22130-nm albumin-bound paclitaxel 21Doxorubicin 18Cisplatin 18Albumin-Bound Paclitaxel 18atezolizumab 16Taxes 15Capecitabine 13veliparib 10Nivolumab 9Docetaxel 9Bevacizumab 9olaparib 8liposomal doxorubicin 7Everolimus 7spartalizumab 6durvalumab 6Epirubicin 6trametinib 5pegfilgrastim 5eribulin 5Irinotecan 5Filgrastim 5iniparib 4binimetinib 4apatinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Triple Negative Breast Neoplasms × Oxaliplatin × Clear all
NCT05007106 2025-08-14

KEYVIBE-005

Merck Sharp & Dohme LLC

Phase 2 Completed
613 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT02658214 2020-08-20

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

AstraZeneca

Phase 1 Completed
32 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡